The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,608,247 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 150 grants at over 100 hospitals in 17 countries.




Institute of Cancer Research - $102,432

Amount
$102,432.00
Date
October 2017

Combinational strategies alongside ACVR1 inhibition in DIPG

The Regents of the University of California - $70,000

Amount
$70,000.00
Date
October 2017

An Open Label Single Arm Phase I/II study of MTX110 delivered by convection-enhanced delivery (CED) in patients with diffuse intrinsic pontine glioma (DIPG) previously treated with external beam radiation therapy

The Hospital for Sick Children - $100,560

Amount
$100,560.00
Date
October 2017

MRI Guided Focused Ultrasound: Towards Clinical Translation in Diffuse Intrinsic Pontine Glioma (DIPG)

Texas Children's Hospital and Ann & Robert H. Lurie Children's Hospital of Chicago - $200,000

Amount
$200,000.00
Date
October 2017

Targeting DIPG through Combining a Super-activator (MCB-613) of Steroid Receptor Co-activators with Radiation.

Gustave Roussy - $101,868

Amount
$101,868.00
Date
October 2017

Elucidating the underlying mechanisms of radio resistance at diagnosis and relapse in DIPG

Ospedale Pediatrico Bambino Gesu - $98,987

Amount
$98,987.00
Date
October 2017

Investigating the role of DIPG-derived exosomes in tumor growth and invasion

Memorial Sloan Kettering Cancer Center - $100,000

Amount
$100,000.00
Date
October 2017

Targeting EZH2 as a therapeutic strategy in DIPG

Dana-Farber Cancer Institute - $100,000

Amount
$100,000.00
Date
October 2017

Defining the Cellular Architecture of Diffuse Intrinsic Pontine Glioma through Large-Scale Single-cell RNA-sequencing analyses

The Hospital of Sick Children - $162,828

Amount
$162,828.00
Date
October 2017

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: an in vitro and in vivo preclinical study

Stanford University - $200,000

Amount
$200,000.00
Date
October 2017

Targeting neuronal activity regulated DIPG infiltration

Children's Cancer Institute (AU) - $185,706

Amount
$185,706.00
Date
October 2017

Developing novel combination therapeutic approaches for DIPG targeting Polo-like Kinase 1

Children's National Medical Center - $200,000

Amount
$200,000.00
Date
October 2017

Validation of TAK228 as an effective drug for treating children with DIPG

Ann & Robert H. Lurie Children's Hospital - $100,000

Amount
$100,000.00
Date
October 2017

Determine the efficacy of BMP and MEK inhibitors with RT to treat ACVR1 mutant DIPG

Anschutz Medical Campus - $50,000

Amount
$50,000.00
Date
September 2017

Toward a Multimodality Cure for DIPG: Investigation of Intratumoral Drug Penetration and Craniospinal Irradiation.

Massachusetts General Hospital - $50,000

Amount
$50,000.00
Date
September 2017

Repurposing Mefloquine for Diffuse Intrinsic Pontine Glioma Therapy